<code id='064416E487'></code><style id='064416E487'></style>
    • <acronym id='064416E487'></acronym>
      <center id='064416E487'><center id='064416E487'><tfoot id='064416E487'></tfoot></center><abbr id='064416E487'><dir id='064416E487'><tfoot id='064416E487'></tfoot><noframes id='064416E487'>

    • <optgroup id='064416E487'><strike id='064416E487'><sup id='064416E487'></sup></strike><code id='064416E487'></code></optgroup>
        1. <b id='064416E487'><label id='064416E487'><select id='064416E487'><dt id='064416E487'><span id='064416E487'></span></dt></select></label></b><u id='064416E487'></u>
          <i id='064416E487'><strike id='064416E487'><tt id='064416E487'><pre id='064416E487'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:explore    - browse:41
          Stock exchange
          Drew Angerer/Getty Images

          Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

          On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

          advertisement

          “We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          hotspot